Anatomical Sites of GLP Release
Glucagon-like peptide-1 (GLP-1) is released from three primary anatomical sites: L-enteroendocrine cells in the terminal ileum and proximal colon (the predominant source), pancreatic islet cells, and neurons in the nucleus tractus solitarius in the brainstem 1.
Primary Release Sites
Intestinal L-Cells (Predominant Source)
The major source of circulating GLP-1 is the L-enteroendocrine cells located in the distal small intestine (terminal ileum) and proximal colon 1. These cells release GLP-1 in response to:
- Glucose loads
- Triglycerides and fatty acids
- Amino acids
- Specific nutrients in the colonic lumen 2
The intestinal release follows nutrient ingestion and represents the primary mechanism for the "incretin effect," where oral glucose produces greater insulin secretion compared to intravenous glucose 1.
Pancreatic Islet Cells
GLP-1 is also secreted by islet cells within the pancreas 1. This represents a paracrine source rather than an endocrine one, suggesting local regulatory functions within the pancreatic microenvironment 3.
Central Nervous System
Preproglucagon (PPG) neurons in the nucleus tractus solitarius of the brainstem produce and release GLP-1 centrally 1, 4. This brain-derived GLP-1 serves as the physiological agonist for brain GLP-1 receptors and is involved in:
- Termination of large meals
- Inhibition of water intake
- Reward processing
- Autonomic functions
- Stress responses 5, 4
Clinical Relevance
The rapid metabolism of intestinally-released GLP-1 by dipeptidyl peptidase-4 (DPP-4) results in an extremely short half-life of approximately 2 minutes 1. This rapid degradation, combined with low circulating concentrations, suggests that endogenous GLP-1 primarily acts through neural or paracrine mechanisms rather than as a traditional endocrine hormone under physiologic conditions 3, 6.
The exception occurs after bariatric surgery (gastric bypass or sleeve gastrectomy), where substantial increases in postprandial GLP-1 release can achieve concentrations sufficient for true endocrine signaling 3.